International Journal of Molecular Sciences: Special Issue New Insights into Immune Dysregulation Disorders

[Sly Saint]

https://www.mdpi.com/journal/ijms/special_issues/F53B1U44YC

The Special Issue entitled "New Insights into Immune Dysregulation Disorders" in the International Journal of Molecular Sciences will present groundbreaking research on the molecular mechanisms of immune dysregulation disorders, encompassing autoimmune conditions, primary immunodeficiencies, and autoinflammatory disorders. It will highlight advancements in understanding specific genes, signalling pathways, and molecular interactions in the pathogenesis of these disorders. Advanced techniques, such as next-generation sequencing, CRISPR gene editing, and omics (proteomics, lipidomics, and metabolomics), will be utilised to uncover new molecular targets and biomarkers for early diagnosis and treatment. This Special Issue will discuss how this knowledge will lead to precision medicine approaches, including targeted biologics and gene therapies, aimed at restoring immune balance. By focusing on the molecular level of these conditions, this Special Issue aims to pave the way for novel therapeutic interventions that could significantly improve patient outcomes.

Insights into the Complex Biological Network Underlying Myalgic Encephalomyelitis/Chronic Fatigue Syndrome​

• Dobrina Dudova,
• Martina Bozhkova,
• Steliyan Petrov,
• Ralitsa Nikolova,
• Teodora Kalfova,
• Mariya Ivanovska,
• Katya Vaseva,
• Maria Nikolova and
• Ivan N. Ivanov

Int. J. Mol. Sci.2026, 27(1), 268;https://doi.org/10.3390/ijms27010268
-
25 December 2025
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating multisystem disorder characterized by immune dysregulation, metabolic impairments, neuroendocrine disturbances, endothelial dysfunction, and gastrointestinal abnormalities....

Show more
Full Article
Select article for export

• Review
• 

1 Citations

4,611 Views

26 Pages
Download PDF

Gulf War Illness, Fibromyalgia, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID Overlap in Common Symptoms and Underlying Biological Mechanisms: Implications for Future Therapeutic Strategies​

• David Mantle,
• Joan Carles Domingo,
• Beatrice Alexandra Golomb and
• Jesús Castro-Marrero

Int. J. Mol. Sci.2025, 26(18), 9044;https://doi.org/10.3390/ijms26189044
-
16 September 2025
Although Gulf War Illness (GWI), fibromyalgia (FM), myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and long COVID have distinct origins, in this article we have reviewed evidence that these disorders comprise a group of so-call
ed low-energy associated disorders with overlapping common symptoms underlying pathology. In particular, evidence for mitochondrial dysfunction, oxidative stress, inflammation, immune dysregulation, neuroendocrine dysfunction, disrupted brain–gut-microbiome axis, apoptosis/ferroptosis and telomere shortening as common features in the pathogenesis of these disorders has been identified. Given the role of coenzyme Q10 (CoQ10) in promoting normal mitochondrial function, as an antioxidant, antiinflammatory and antiapoptotic and antiferroptotic agent, there is a rationale for supplementary CoQ10 in the management of these disorders. The reported benefits of supplementary CoQ10 administration in GWI, FM, ME/CFS and long COVID have been reviewed; the potential benefit of supplementary CoQ10 in reducing telomere shortening and improving the efficiency of stem cell transfer relevant has also been identified as promising therapeutic strategies in these disorders. This review advances beyond previous systematic reviews and consensus statements on overlapping similar symptoms and underlying biological pathomechanisms in these complex disorders.

Show less
Full Article

 

[Utsikt]

Several studies have shown that CoQ10 supplementation can reduce fatigue and improve quality of life in individuals with ME/CFS. Castro-Marrero et al. reported supplementation with CoQ10 and nicotinamide adenine dinucleotide (NADH) improved fatigue in ME/CFS

They reference this study, which found «statistically significant», but completely meaningless differences for a few of very many outcomes in a blinded trial with placebo.

If that is representative for the rest of the paper I think it can safely be dismissed..